DK1605965T3 - Anvendelse af saposin-beslægtede proteiner til forebyggelse og behandling af obesitet, diabetes og/eller metabolisk syndrom - Google Patents
Anvendelse af saposin-beslægtede proteiner til forebyggelse og behandling af obesitet, diabetes og/eller metabolisk syndromInfo
- Publication number
- DK1605965T3 DK1605965T3 DK04739073.7T DK04739073T DK1605965T3 DK 1605965 T3 DK1605965 T3 DK 1605965T3 DK 04739073 T DK04739073 T DK 04739073T DK 1605965 T3 DK1605965 T3 DK 1605965T3
- Authority
- DK
- Denmark
- Prior art keywords
- saposin
- obesity
- diabetes
- prevention
- treatment
- Prior art date
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 102000017852 Saposin Human genes 0.000 title 1
- 108050007079 Saposin Proteins 0.000 title 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/60—New or modified breeds of invertebrates
- A01K67/61—Genetically modified invertebrates, e.g. transgenic or polyploid
- A01K67/65—Genetically modified arthropods
- A01K67/68—Genetically modified insects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03006948 | 2003-03-26 | ||
| PCT/EP2004/003244 WO2004084930A1 (en) | 2003-03-26 | 2004-03-26 | Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1605965T3 true DK1605965T3 (da) | 2013-04-15 |
Family
ID=33040919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04739073.7T DK1605965T3 (da) | 2003-03-26 | 2004-03-26 | Anvendelse af saposin-beslægtede proteiner til forebyggelse og behandling af obesitet, diabetes og/eller metabolisk syndrom |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20060275274A1 (da) |
| EP (1) | EP1605965B1 (da) |
| DK (1) | DK1605965T3 (da) |
| ES (1) | ES2402096T3 (da) |
| WO (1) | WO2004084930A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013203640B2 (en) * | 2007-06-22 | 2017-04-13 | Children's Medical Center Corporation | Methods and uses thereof of prosaposin |
| CA3056116A1 (en) | 2007-06-22 | 2008-12-31 | Randolph Watnick | Methods and uses thereof of prosaposin |
| EP2513137B1 (en) * | 2009-12-17 | 2018-02-28 | Children's Medical Center Corporation | Saposin-a derived peptides and uses thereof |
| CA2860226C (en) | 2011-12-22 | 2022-10-18 | Randolph S. Watnick | Saposin-a derived peptides and uses thereof |
| ES3007461T3 (en) | 2013-03-14 | 2025-03-20 | Childrens Medical Center | Use of cd36 to identify cancer subjects for treatment by a psap peptide |
| US10646541B2 (en) | 2014-03-26 | 2020-05-12 | Children's Medical Center Corporation | Cyclic prosaposin peptides and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0240550A4 (en) * | 1985-09-26 | 1989-09-19 | Genetics Inst | TENSIO-ACTIVE PULMONARY PROTEINS. |
| US4918161A (en) * | 1985-09-26 | 1990-04-17 | Genetics Institute, Inc. | Low molecular weight pulmonary surfactant proteins |
| US6271196B1 (en) * | 1996-03-05 | 2001-08-07 | Regents Of The University Of Ca | Methods of alleviating neuropathic pain using prosaposin-derived peptides |
| CA2337438A1 (en) * | 1998-07-13 | 2000-01-20 | Parkash S. Gill | Novel inhibitors of angiogenesis and tumor growth |
| SE523817C2 (sv) * | 1999-02-05 | 2004-05-18 | Corline Systems Ab | Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler |
| WO2000062862A1 (en) * | 1999-04-15 | 2000-10-26 | South Eastern Sydney Area Health Service | Method of prophylaxis and treatment of diabetes |
| JP2001010972A (ja) * | 1999-06-30 | 2001-01-16 | Masahiro Sakanaka | プロサポシン関連ペプチドからなる細胞保護剤 |
| EP1224259A4 (en) * | 1999-09-27 | 2005-04-27 | Univ Florida | INVERSION OF INSULIN DEPENDENT DIABETES BY ISOLATED STEM CELLS, PROGENITOR ISLANDIC CELLS, AND INSULAR TYPE STRUCTURES |
| WO2001039784A1 (en) * | 1999-12-06 | 2001-06-07 | The General Hospital Corporation | Pancreatic stem cells and their use in transplantation |
| AU2001233715A1 (en) * | 2000-01-26 | 2001-08-07 | Memorec Medical Molecular Research Cologne Stoffel Gmbh | Dermo- and gastro-specific sphingolipid activator |
-
2004
- 2004-03-26 DK DK04739073.7T patent/DK1605965T3/da active
- 2004-03-26 WO PCT/EP2004/003244 patent/WO2004084930A1/en not_active Ceased
- 2004-03-26 ES ES04739073T patent/ES2402096T3/es not_active Expired - Lifetime
- 2004-03-26 US US10/550,985 patent/US20060275274A1/en not_active Abandoned
- 2004-03-26 EP EP04739073A patent/EP1605965B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2402096T3 (es) | 2013-04-26 |
| EP1605965B1 (en) | 2012-12-26 |
| WO2004084930A1 (en) | 2004-10-07 |
| US20060275274A1 (en) | 2006-12-07 |
| EP1605965A1 (en) | 2005-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1711184T3 (da) | (3-Oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamid-derivater og beslægtede forbindelser som glycogenphosphorylaseinhibitorer til behandling af diabetes og fedme | |
| DK3524261T5 (da) | Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt | |
| DK1773361T3 (da) | Sammensætning baseret på probiotiske bakterier og anvendelse deraf til forebyggelse og/eller behandling af respiratoriske sygdomme og/eller infektioner og til forbedring af en intestinale funktionalitet | |
| NO20053041D0 (no) | Behandling av diabetes. | |
| IL219915A0 (en) | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | |
| NO20044272L (no) | Legemiddel for behandling og/eller forebyggelse av kronisk avstotning | |
| DK1830869T3 (da) | Fremgangsmåde til behandling eller profylakse | |
| DK1765388T3 (da) | Kombinationsterapi til forebyggelse eller behandling af alzheimer's sygdom, og kit dertil | |
| DK1824475T3 (da) | Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol | |
| DK1740197T3 (da) | Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki | |
| DK1771201T3 (da) | Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom | |
| DK1487541T3 (da) | Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme | |
| NO20055686L (no) | Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav. | |
| DK2018184T3 (da) | Anti-vegf-b-antistof til behandling eller forebyggende behandling af type 2-diabetes eller metabolisk syndrom | |
| DK1737961T3 (da) | Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf | |
| DK1694342T3 (da) | Fremgangsmåder til anvendelse af gelsolin til behandling eller forebyggelse af bakteriel sepsis | |
| DK1663291T3 (da) | Rekombinante lubricinmolekyler og anvendelser deraf | |
| DK1848415T3 (da) | Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose | |
| DK1802749T3 (da) | KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser | |
| DK1700598T3 (da) | Antiproliferativ kombinationsterapi med satraplatin eller JM118 og docetaxel | |
| NO20035056D0 (no) | Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes | |
| DE602005027400D1 (de) | Il-22 zur behandlung von fettleibigkeit, diabetes, hyperlipidämie, hyperglykämie und insulinresistenz | |
| DK1605965T3 (da) | Anvendelse af saposin-beslægtede proteiner til forebyggelse og behandling af obesitet, diabetes og/eller metabolisk syndrom | |
| DK1355668T3 (da) | Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom | |
| DK2193789T3 (da) | Anvendelse af 3,5-dihydroxytoluen eller derivater deraf i fremstillingen af medicin og funktionelle fødevarer til behandling eller forebyggelse af depression |